HUTCHMED China Ltd Cash Flow Conversion Efficiency
HUTCHMED China Ltd cash flow conversion efficiency. Based on the latest financial reports, HUTCHMED China Ltd (HCM) has a cash flow conversion efficiency ratio of 0.003x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX4.12 Million ≈ $501.10 USD) by net assets (GBX1.25 Billion ≈ $152.24K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of HUTCHMED China Ltd (2005–2025)
Cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. This chart illustrates how HUTCHMED China Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HCM stock price for real-time trading data and today's change.
HUTCHMED China Ltd Cash Flow Conversion Ratio Explained
HUTCHMED China Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
HUTCHMED China Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HUTCHMED China Ltd ranked by their cash flow conversion efficiency. Also see HCM company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kingsmen Resources Ltd
V:KNG
|
-0.028x |
|
AJ Advance Technology Public Company Limited
BK:AJA
|
-0.019x |
|
Cobalt Blue Holdings Ltd
AU:COB
|
-0.121x |
|
Reitmans Canada Ltd
V:RET
|
0.172x |
|
Boat Rocker Media Inc
TO:BRMI
|
0.095x |
|
ELUON Corporation
KQ:065440
|
0.115x |
|
AIRA Factoring Public Company Limited
BK:AF
|
-0.265x |
|
Ogunsen AB Series B
ST:OGUN-B
|
0.125x |
Annual Cash Flow Conversion Efficiency for HUTCHMED China Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of HUTCHMED China Ltd from 2005 to 2025. Review free cash flow generation of HUTCHMED China Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | GBX1.25 Billion ≈ $152.03K |
GBX-64.67 Million ≈ $-7.87K |
-0.052x | -8137.94% |
| 2024-12-31 | GBX771.85 Million ≈ $93.91K |
GBX497.00K ≈ $60.47 |
0.001x | -99.78% |
| 2023-12-31 | GBX743.39 Million ≈ $90.45K |
GBX219.26 Million ≈ $26.68K |
0.295x | +169.93% |
| 2022-12-31 | GBX636.87 Million ≈ $77.49K |
GBX-268.60 Million ≈ $-32.68K |
-0.422x | -114.67% |
| 2021-12-31 | GBX1.04 Billion ≈ $126.48K |
GBX-204.22 Million ≈ $-24.85K |
-0.196x | -64.27% |
| 2020-12-31 | GBX518.95 Million ≈ $63.14K |
GBX-62.07 Million ≈ $-7.55K |
-0.120x | +53.75% |
| 2019-12-31 | GBX312.90 Million ≈ $38.07K |
GBX-80.91 Million ≈ $-9.84K |
-0.259x | -224.54% |
| 2018-12-31 | GBX412.25 Million ≈ $50.16K |
GBX-32.85 Million ≈ $-4.00K |
-0.080x | -332.07% |
| 2017-12-31 | GBX484.97 Million ≈ $59.01K |
GBX-8.94 Million ≈ $-1.09K |
-0.018x | +60.68% |
| 2016-12-31 | GBX204.06 Million ≈ $24.83K |
GBX-9.57 Million ≈ $-1.16K |
-0.047x | +48.90% |
| 2015-12-31 | GBX102.28 Million ≈ $12.44K |
GBX-9.38 Million ≈ $-1.14K |
-0.092x | -182.34% |
| 2014-12-31 | GBX119.88 Million ≈ $14.59K |
GBX13.36 Million ≈ $1.63K |
0.111x | +132.36% |
| 2013-12-31 | GBX104.84 Million ≈ $12.76K |
GBX5.03 Million ≈ $611.76 |
0.048x | -74.38% |
| 2012-12-31 | GBX83.65 Million ≈ $10.18K |
GBX15.66 Million ≈ $1.91K |
0.187x | +178.34% |
| 2011-12-31 | GBX77.33 Million ≈ $9.41K |
GBX5.20 Million ≈ $632.88 |
0.067x | +123.36% |
| 2010-12-31 | GBX68.81 Million ≈ $8.37K |
GBX-19.82 Million ≈ $-2.41K |
-0.288x | -286.53% |
| 2009-12-31 | GBX75.30 Million ≈ $9.16K |
GBX11.63 Million ≈ $1.41K |
0.154x | +191.37% |
| 2008-12-31 | GBX84.43 Million ≈ $10.27K |
GBX-14.27 Million ≈ $-1.74K |
-0.169x | -91.86% |
| 2007-12-31 | GBX97.61 Million ≈ $11.88K |
GBX-8.60 Million ≈ $-1.05K |
-0.088x | -166.27% |
| 2006-12-31 | GBX109.98 Million ≈ $13.38K |
GBX-3.64 Million ≈ $-442.64 |
-0.033x | -106.81% |
| 2005-12-31 | GBX-28.01 Million ≈ $-3.41K |
GBX-13.60 Million ≈ $-1.65K |
0.485x | -- |
About HUTCHMED China Ltd
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more